These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25137021)

  • 1. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
    El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
    Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer.
    El-Mokadem I; Kidd T; Pratt N; Fleming S; Nabi G
    Oncotarget; 2016 Nov; 7(45):73045-73054. PubMed ID: 27682877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma.
    de Oliveira D; Dall'Oglio MF; Reis ST; Zerati M; Souza IC; Leite KR; Srougi M
    Urol Oncol; 2014 Jul; 32(5):601-6. PubMed ID: 24629495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.
    La Rochelle J; Klatte T; Dastane A; Rao N; Seligson D; Said J; Shuch B; Zomorodian N; Kabbinavar F; Belldegrun A; Pantuck AJ
    Cancer; 2010 Oct; 116(20):4696-702. PubMed ID: 20629029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma.
    Brunelli M; Eccher A; Gobbo S; Ficarra V; Novara G; Cossu-Rocca P; Bonetti F; Menestrina F; Cheng L; Eble JN; Martignoni G
    Mod Pathol; 2008 Jan; 21(1):1-6. PubMed ID: 17906617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma.
    Nejati R; Wei S; Uzzo RG; Poureghbali S; Pei J; Talarchek JN; Ruth K; Dulaimi E; Kutikov A; Testa JR; Al-Saleem T
    Clin Genitourin Cancer; 2020 Feb; 18(1):56-61. PubMed ID: 31648964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH.
    Sanjmyatav J; Matthes S; Muehr M; Sava D; Sternal M; Wunderlich H; Gajda M; Grimm MO; Junker K
    Br J Cancer; 2014 May; 110(10):2537-43. PubMed ID: 24667645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite alteration and immunohistochemical expression profile of chromosome 9p21 in patients with sporadic renal cell carcinoma following surgical resection.
    El-Mokadem I; Lim A; Kidd T; Garret K; Pratt N; Batty D; Fleming S; Nabi G
    BMC Cancer; 2016 Jul; 16():546. PubMed ID: 27465101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
    Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
    Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
    Klatte T; Rao PN; de Martino M; LaRochelle J; Shuch B; Zomorodian N; Said J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    J Clin Oncol; 2009 Feb; 27(5):746-53. PubMed ID: 19124809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
    Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
    J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
    Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
    Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma.
    Narimatsu T; Matsuura K; Nakada C; Tsukamoto Y; Hijiya N; Kai T; Inoue T; Uchida T; Nomura T; Sato F; Seto M; Takeuchi I; Mimata H; Moriyama M
    Cancer Med; 2015 Jan; 4(1):112-24. PubMed ID: 25315157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer.
    Eichenauer T; Simmendinger L; Kluth M; Chirico V; Luebke AM; Höflmayer D; Hinsch A; Jacobsen F; Hube-Magg C; Möller-Koop C; Dahlem R; Fisch M; Rink M; Riechardt S; Tsourlakis MC; Büscheck F; Bernreuther C; Clauditz T; Lebok P; Simon R; Sauter G; Wilczak W; Fraune C
    Urol Oncol; 2020 Jun; 38(6):605.e1-605.e8. PubMed ID: 32241691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
    Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
    Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Prognostic Impact of Chromosome Abnormalities in Clear Cell Renal Cell Carcinoma.
    Palumbo C; Furlan M; Balzarini P; Zanotelli T; Cozzoli A; Veccia A; Francavilla S; Zamboni S; Tardanico R; Simeone C; Antonelli A
    Anticancer Res; 2019 Jun; 39(6):2757-2765. PubMed ID: 31177111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.